EFFICACY OF VENETOCLAX plus OBINUTUZUMAB plus IBRUTINIB COMPARED TO ALTERNATIVE THERAPEUTIC OPTIONS IN THE FIRST-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (FIT POPULATION): A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

被引：0
|
作者：
Stozek-Tutro, A. [1 ]
Reczek, M. [2 ]
Kawalec, P. [3 ]
机构：
[1] Jagiellonian Univ, Doctoral Sch Med & Hlth Sci, Med Coll, Crocow, MA, Poland
[2] HTA Consulting, Krakow, Poland
[3] Jagiellonian Univ, Inst Publ Hlth, Med Coll, Krakow, Poland
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
CO182
引用
收藏
页码：S46 / S46
页数：1
相关论文
共 50 条
  • [31] A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia
    Ladyzynski, Piotr
    Molik, Maria
    Foltynski, Piotr
    CANCER TREATMENT REVIEWS, 2015, 41 (02) : 77 - 93
  • [32] Real-World Healthcare Costs Among Patients With Chronic Lymphocytic Leukemia Receiving First-Line Treatment With Venetoclax plus Obinutuzumab Versus Bruton Tyrosine Kinase Inhibitors
    Ravelo, Arliene
    Patel, Achal
    To, Tu My
    Li, Sophia S.
    Huntington, Scott
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S345 - S345
  • [33] Comparison of venetoclax plus rituximab with B-cell receptor inhibitors in patients with relapsed/refractory chronic lymphocytic leukemia: a systematic review and network Meta-analysis
    Molica, Stefano
    Giannarelli, Diana
    Shanafelt, Tait D.
    LEUKEMIA & LYMPHOMA, 2020, 61 (04) : 955 - 958
  • [34] Comparative efficacy and safety of first-line tyrosine kinase inhibitors in chronic myeloid leukemia: a systematic review and network meta-analysis
    Zhang, Jing-Jing
    Qian, Yu-Lan
    Wu, Zi-Yang
    Li, Yue
    Guan, Ying-Jie
    Sun, Cui
    Fu, Kai-Li
    Mei, Tong-Lin
    Goyal, Gaurav
    Bernasconi, Paolo
    Damiani, Daniela
    Zhu, Jian-Guo
    TRANSLATIONAL CANCER RESEARCH, 2024, 13 (07)
  • [35] Comparative Efficacy of First-Line Chemotherapy-Free Combinations in Chronic Lymphocytic Leukemia (CLL): A Network Meta-Analysis
    Haddad, Philip A.
    Ganey, Nowell
    Gallagher, Kevin M.
    BLOOD, 2020, 136
  • [36] Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study
    Tam, Constantine S.
    Siddiqi, Tanya
    Allan, John N.
    Kipps, Thomas J.
    Flinn, Ian W.
    Kuss, Bryone J.
    Opat, Stephen
    Barr, Paul M.
    Tedeschi, Alessandra
    Jacobs, Ryan
    Badoux, Xavier C.
    Ghia, Paolo
    Sukbuntherng, Juthamas
    Salem, Ahmed Hamed
    Russell, Kristin
    Eckert, Karl
    Zhou, Cathy
    Ninomoto, Joi
    James, Danelle F.
    Wierda, William G.
    BLOOD, 2019, 134
  • [37] Efficacy and Toxicity of Lenalidomide for Treatment of Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis
    Kotapati, Sravanthi
    Selene, Insija Ilyas
    Shafqat, Madeeha
    Hassan, Syeda Fatima
    Shah, Zunairah
    Akbar, Arshia
    Rehman, Owais Ur
    Syed, Tariq Iqtidar Sadiq
    Ghani, Marium
    Abdullah, Syed Maaz
    Khan, Maimoona
    Jose, Jemin Aby
    Anwer, Faiz
    BLOOD, 2019, 134
  • [38] First-line treatments for chronic lymphocytic leukaemia: interpreting efficacy data by network meta-analysis
    Messori, Andrea
    Fadda, Valeria
    Maratea, Dario
    Trippoli, Sabrina
    ANNALS OF HEMATOLOGY, 2015, 94 (06) : 1003 - 1009
  • [39] First-line treatments for chronic lymphocytic leukaemia: interpreting efficacy data by network meta-analysis
    Andrea Messori
    Valeria Fadda
    Dario Maratea
    Sabrina Trippoli
    Annals of Hematology, 2015, 94 : 1003 - 1009
  • [40] A systematic review and network meta-analysis of first-line treatment options in patients metastatic renal cell carcinoma
    Bin Riaz, Irbaz
    Ryu, Alexander J.
    Yao, Yuan
    Siddiqi, Rabbia
    Mathew, Jessey
    Sipra, Qurat Ul Ain Riaz
    Zahoor, Haris
    Wang, Zhen
    Murad, M. Hassan
    Pagliaro, Lance C.
    Costello, Brian Addis
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
12345